The FDA has updated the label for Merck’s Winrevair (sotatercept-csrk) following results from the Phase III ZENITH trial, confirming the therapy’s ability to reduce the risk of clinical worsening ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback